TRILLIUM THERAPEUTICS DOSES FIRST PATIENT WITH TTI-621 IN PHASE 1 SOLID TUMOR TRIAL

On January 31, 2017 Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that it has initiated dosing in its second Phase 1 clinical trial with TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides (Press release, Trillium Therapeutics, JAN 31, 2017, View Source [SID1234517607]). Trillium is developing TTI-621 as a novel checkpoint inhibitor of the innate immune system, and the drug is currently being evaluated in an ongoing 10-cohort Phase 1b study in patients with relapsed or refractory hematologic malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

“To our knowledge, this is the first patient to ever receive an intratumoral injection of a CD47 blocking agent,” commented Dr. Bob Uger, Trillium’s Chief Scientific Officer. “We believe this approach, which aims to achieve a high local concentration of TTI-621 and employs frequent biopsy analysis, will help us better understand the effects of TTI-621 on the tumor microenvironment and provide critical information for the development of rational combination therapies.”

This two-part clinical trial is designed as a multi-center, open-label Phase 1a/1b trial, and is evaluating TTI-621 as a single-agent in patients that have relapsed or refractory percutaneously accessible solid tumors or mycosis fungoides (NCT02890368). The escalation phase will include single or multiple doses of TTI-621 delivered by intratumoral injections, which will be followed by an expansion phase during which one or more selected dose levels of TTI-621 will be tested.